We are thrilled to share that Biocytogen will attend the 24th San Diego Biopharma Conference on September 26th in Del Mar, CA. Hosted by SABPA, the conference gathers over 500 life science professionals to explore the latest developments in biotechnology and pharmaceutical innovation. Come connect with our team and learn how we are accelerating antibody discovery and preclinical drug development.
What is SABPA?
The SoCal Association for Biomedical and Pharmaceutical Advancements (SABPA) is a 501(c)(3) nonprofit organization, established in 2002 by professionals and scholars from the Chinese community in San Diego. By 2005, SABPA had expanded its presence to Orange County and Los Angeles. Today, the organization boasts over 3,500 members and subscribers, including scholars, professionals, and entrepreneurs in Southern California's biotech and pharmaceutical industries.
Event Overview
Date: September 26th, 2026
Venue: Hilton San Diego/Del Mar, 15575 Jimmy Durante Blvd, Del Mar, CA 92014
Event Schedule
For more information, please refer to the SABPA website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
